Adult versus Pediatric @entity521 : The M.D. Anderson XXXX Center Experience.

@entity1 @entity5 @entity521
Background. Staging and treatment of @entity521 has yet to be formalized. We sought to determine the utility of the pediatric classification system in adults and determine the efficacy of different treatment modalities. Methods. Medical records of 118 adults ( @entity1 >17 years old) and 112 pediatric @entity1 (ages 2-17), who were treated for @entity521 at M.D. Anderson @entity5 Center from January 1994 to September 2012, were reviewed. International @entity521 risk group (INRG) variables were abstracted. The primary outcome of interest was actuarial progression-free survival. Results. Median age of pediatric @entity1 was 5 years (range 3-16) and 47 years (range 18-82) for adult @entity1 . There were no differences in PFS or OS between stage-matched risk categories between pediatric and adult @entity1 (L1-P = 0.40, L2-P = 0.54, and M-P = 0.73). In the treatment of L1 disease, median PFS for adults treated with surgery and radiation was 11.1 months compared with single modality local treatment    chemotherapy (6.4 and 5.1 months, resp.; P = 0.07). Median PFS in L2 adult @entity1 was 5.2 months with local therapy and 4 months with the addition of chemotherapy (P = 0.23). Conclusions. Adult and pediatric @entity1 with @entity521 achieve similar survival outcomes. INRG classification should be employed to stratify @entity521 @entity1 and help select treatment.
